Reddick C L, Singh M N, Chalmers R J G
The Dermatology Centre, University of Manchester, Salford Royal Foundation Hospital, Manchester, United Kingdom.
Dermatol Online J. 2010 Aug 15;16(8):15.
Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are chronic inflammatory dermatoses that can be a challenge to treat. A role for TNF-alpha in their pathogenesis has been postulated in the literature. A therapeutic benefit of infliximab has been reported in recalcitrant cases of both conditions. To date, there is less evidence about the use of adalimumab for these conditions. We report a patient with severe superficial PG on a background of HS, which responded to adalumimab therapy after failure of infliximab therapy.
坏疽性脓皮病（PG）和化脓性汗腺炎（HS）是慢性炎症性皮肤病，治疗起来可能具有挑战性。文献中已假定肿瘤坏死因子-α在其发病机制中起作用。英夫利昔单抗对这两种疾病的顽固性病例均有治疗益处的报道。迄今为止，关于阿达木单抗用于这些疾病的证据较少。我们报告了1例以HS为背景的重度浅表性PG患者，在英夫利昔单抗治疗失败后，该患者对阿达木单抗治疗有反应。
